PP_1170x120_10-25-21

exemestane tablets

Aurobindo gets FDA approval for exemestane tablets USP, 25 mg

Aurobindo gets FDA approval for exemestane tablets USP, 25 mg

EAST WINDSOR, N.J. – Aurobindo Pharma has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application exemestane tablets USP, 25 mg. Aurobindo Pharma’s exemestane tablets are an AB-rated generic equivalent to the reference listed drug (RLD), AROMASIN Tablets, manufactured by Pfizer. Exemestane tablets are indicated for adjuvant treatment of

Mylan releases Aromasin generic in U.S.

Mylan releases Aromasin generic in U.S.

PITTSBURGH — Mylan N.V. has launched exemestane tablets 25 mg, a breast cancer medication, in the United States. Mylan said its exemestane product is a generic version of Aromasin tablets from Pfizer Inc. Exemestane is indicated for the treatment of certain types of breast cancer in women after menopause. The medication works by reducing estrogen